ArticleSTAR protocols2026

Protocol for high-throughput droplet-engineered TIL-retaining tumor organoids in triple-negative breast cancer.

Xiaolong Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.